Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ELVWV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ZA202500415A-ADC Example 4
|
|||||
| Synonyms |
ZA202500415A-ADC Example 4
Click to Show/Hide
|
|||||
| Organization |
MYRICX PHARMA LIMITED | IMPERIAL COLLEGE INNOVATIONS LIMITED
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
5
|
|||||
| Structure |
|
|||||
| Antibody Name |
Ifinatamab
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
NMT inhibitor 1
|
Payload Info | ||||
| Therapeutic Target |
N-Myristoyltransferase (NMT)
|
Target Info | ||||
| Linker Name |
ZA202500415A-ADC-Example-1-Linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
104.40%
|
|||
| Method Description |
Cell line-derived xenograft models were established in male NOD SCID mice, by subcutaneous injection of 1x107 (LNCaP) tumor cells, and treatmen with 5mg/kg ADC (Q7DƧ) after tumor volume about 80-100mm3. Determined tumor volume after the experiment, measured at day 28.
|
||||
| In Vivo Model | LNCaP prostate cancer xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
108.31%
|
|||
| Method Description |
Cell line-derived xenograft models were established in non-castrated male CB17/SCID mice, by subcutaneous injection of 1x107 (VCaP) tumor cells, and treatmen with 2.5mg/kg ADC (QWƦ) after tumor volume about 162.16mm3. Determined tumor volume after the experiment, measured at day 17.
|
||||
| In Vivo Model | VCaP prostate cancer xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
112.40%
|
|||
| Method Description |
Cell line-derived xenograft models were established in male NOD SCID mice, by subcutaneous injection of 1x107 (LNCaP) tumor cells, and treatmen with 10mg/kg ADC (Q7DƧ) after tumor volume about 80-100mm3. Determined tumor volume after the experiment, measured at day 28.
|
||||
| In Vivo Model | LNCaP prostate cancer xenograft model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
114.03%
|
|||
| Method Description |
Cell line-derived xenograft models were established in non-castrated male CB17/SCID mice, by subcutaneous injection of 1x107 (VCaP) tumor cells, and treatmen with 10mg/kg ADC (QWƦ) after tumor volume about 162.16mm3. Determined tumor volume after the experiment, measured at day 17.
|
||||
| In Vivo Model | VCaP prostate cancer xenograft model | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
114.69%
|
|||
| Method Description |
Cell line-derived xenograft models were established in non-castrated male CB17/SCID mice, by subcutaneous injection of 1x107 (VCaP) tumor cells, and treatmen with 5mg/kg ADC (QWƦ) after tumor volume about 162.16mm3. Determined tumor volume after the experiment, measured at day 17.
|
||||
| In Vivo Model | VCaP prostate cancer xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.154 uM
|
|||
| Method Description |
LNCaP Cells were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added at serial dilutions of each test compound spanning a concentration range of either 50 nM to 0.005 nM for the various ADCs. Cell proliferation was measured after 144 hours exposure, by CellTiter-Glo 2.0 Solution Cell Viability Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Prostate carcinoma | LNCaP cells | CVCL_0395 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.158 uM
|
|||
| Method Description |
VCaP Cells were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added at serial dilutions of each test compound spanning a concentration range of either 50 nM to 0.005 nM for the various ADCs. Cell proliferation was measured after 144 hours exposure, by CellTiter-Glo 2.2 Solution Cell Viability Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Prostate carcinoma | VCaP cells | CVCL_2235 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.345 uM
|
|||
| Method Description |
C42 Cells were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added at serial dilutions of each test compound spanning a concentration range of either 50 nM to 0.005 nM for the various ADCs. Cell proliferation was measured after 144 hours exposure, by CellTiter-Glo 2.1 Solution Cell Viability Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Prostate carcinoma | C4-2 cells | CVCL_4782 | ||